Experimental and Clinical Evaluation in Man of Hexamethonium (C6), A New Ganglionic Blocking Agent

Publisher Website
Google Scholar
Abstract
In man, C6, a new ganglionic blocking agent (50 mg. intravenously) produced inhibition of the Valsalva, tiltback and cold pressor vasopressor responses. Marked increases in digital blood flow and skin temperature with inhibition of digital reflexes to "noxious" stimuli were consistently observed (room temperature 70 F.). The increase in skin temperature was greater and more lasting than following Priscoline or tetraethylammonium chloride. Except for severe postural hypotension, side effects were minimal. Clinically the drug may be useful in the evaluation of sympathetic vasoconstriction in peripheral vascular disease as well as in the treatment of acute neurogenic vasospasm.